ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1670

Large Vessel Vasculitis: Estimating Disease Activity In Patients With Inflammatory Thoracic Aortic Aneurysms

Alison Clifford1, Tiffany M. Clark2, Douglas Johnston3, Gosta Pettersson3, Eric Roselli4, E. Rene Rodriguez5, Edward Soltesz3, Lars Svensson4, Carmela Tan6 and Gary S. Hoffman1, 1Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, 2Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH, 3Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH, 4Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH, 5Department of Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, OH, 6Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, OH

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Disease Activity and large vessel vasculitis

  • Tweet
  • Email
  • Print
Session Information

Title: Vasculitis II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Thoracic aortic aneurysms due to large vessel vasculitis may be a sign of ongoing inflammation or the sequelae of previous damage to the arterial wall.  Ongoing inflammation in the aorta is usually estimated indirectly using clinical features, inflammatory markers and imaging characteristics. Whether these surrogates accurately reflect inflammation within the vessel wall is not known.

Methods: We retrospectively reviewed the clinical, laboratory and imaging data for patients in whom aortitis was histologically demonstrated at the time of reconstruction for thoracic aortic aneurysms (May 2011-December 2012). ACR classification criteria were used to define vasculitis subtype. Pre- and post-operative assessments of disease activity were estimated using the NIH criteria for active disease.

Results: Among 126 consenting study patients who underwent repair of thoracic aortic aneurysms, 14 (11%) had histological features of aortitis. Thirteen specimens (93%) had persistent inflammatory infiltrates, and 1 had features of healed aortitis. Seven patients met criteria for Giant Cell Arteritis, 2 for Takayasu’s arteritis, 4 for Isolated Aortitis, and 1 for Sarcoidosis. Median duration of disease prior to surgery was 35.5 months (range 0-180).  At the time of surgery, only 2 of 10 patients (20%) with known systemic disease met criteria for active disease, while the remaining 8 (80%) were felt to be in clinical remission, yielding a sensitivity of 22% and specificity of 100% for the NIH criteria for determining active disease.  When assessed over 1 year pre-operatively, 5 of 10 patients (50%) met criteria for active disease, increasing the sensitivity of NIH criteria to 44%.  Post-operatively, only 1 of 13 (7%) patients met criteria for active disease.  Two patients developed new vascular lesions during follow-up, at median of 3 months post-operatively, and 2 patients died.

Conclusion:   At the time of surgery only 20% of patients with aortitis met criteria for active disease based on indirect clinical features, while 93% demonstrated ongoing inflammation on biopsy, indicating that indirect estimates of thoracic aortic inflammation are insensitive in patients with aneurysms.  These findings emphasize the need for improved markers for assessing disease activity in patients with large vessel vasculitis.

 


Disclosure:

A. Clifford,
None;

T. M. Clark,
None;

D. Johnston,
None;

G. Pettersson,
None;

E. Roselli,
None;

E. R. Rodriguez,
None;

E. Soltesz,

St. Jude Medical ,

8,

TransMedics,

9;

L. Svensson,
None;

C. Tan,
None;

G. S. Hoffman,

Vasculitis Foundation,

2,

DSMD from Roche and Sanofi-Aventis,

5.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/large-vessel-vasculitis-estimating-disease-activity-in-patients-with-inflammatory-thoracic-aortic-aneurysms/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology